Chargement en cours...
Impact of Rituximab and Host/Donor Fc Receptor Polymorphisms after Allogeneic Hematopoietic Cell Transplantation for CD20(+) B Cell Malignancies
We previously reported a 24% 1-year relapse rate in 93 older or medically unfit patients with CD20(+) B cell malignancies after allogeneic hematopoietic cell transplantation (HCT) with low-intensity conditioning. The current prospective study tested the hypothesis that disease relapse could be reduc...
Enregistré dans:
| Publié dans: | Biol Blood Marrow Transplant |
|---|---|
| Auteurs principaux: | , , , , , , |
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
2020
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7549403/ https://ncbi.nlm.nih.gov/pubmed/32693210 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.bbmt.2020.07.014 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|